Evidence map›Paper›PMID 32684120›Full record

ArticleJournal of feline medicine and surgery2021

LOPH: a novel chemotherapeutic protocol for feline high-grade multicentric or mediastinal lymphoma, developed in an area endemic for feline leukemia virus.

Rodrigo S Horta, Larissa M Souza, Bruna V Sena, Isabella O Almeida, Tâmara A Jaretta, Marcela M Pimenta, Archivaldo Reche Júnior

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of feline medicine and surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Effects of Chemotherapy on Hematological Parameters and CD4Animals : an open access journal from MDPI · 2022
    Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Rodrigo S HortaDepartment of Veterinary Medicine and Surgery, Veterinary School, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Larissa M SouzaDepartment of Veterinary Medicine, Vila Velha University, Vila Velha, ES, Brazil.ORCID 0000-0001-9102-7222
Bruna V SenaProf. Ricardo Alexandre Hippler Veterinary Hospital, Vila Velha University, Vila Velha, ES, Brazil.
Isabella O AlmeidaProf. Ricardo Alexandre Hippler Veterinary Hospital, Vila Velha University, Vila Velha, ES, Brazil.
Tâmara A JarettaDepartment of Veterinary Medicine, Vila Velha University, Vila Velha, ES, Brazil.
Marcela M PimentaTreevet, Belo Horizonte, MG, Brazil.
Archivaldo Reche JúniorFaculty of Veterinary Medicine and Zootechny, University of São Paulo (USP), São Paulo, Brazil.
Universidade Vila Velha · BRUniversidade de São Paulo · BRUniversidade Federal de Minas Gerais · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of this study was to establish the safety and efficacy of a novel multidrug lomustine-based chemotherapeutic protocol for cats with high-grade multicentric or mediastinal lymphoma, in an area endemic for feline leukemia virus (FeLV).

methodsThis prospective study included owned cats, diagnosed (cytologically) with multicentric or mediastinal lymphoma and treated with the LOPH (lomustine, vincristine [Oncovin; Antibióticos do Brasil], prednisolone and hydroxydaunorubicin [doxorubicin]) protocol. A complete blood count was performed before every chemotherapy session and any significant abnormalities recorded as possible related toxicities. Median survival time (MST) and disease-free interval were estimated by Kaplan-Meier curves.

resultsTwenty-one cats were included in this study. Nineteen (90.5%) tested positive for FeLV and were therefore considered to have persistent viremia. Complete response was reported in 81% (n = 17/21), while three had partial remission and one had no response. Seven cats finished the induction protocol within 20-31 weeks (23.1 ± 4.5; median 20) and all seven received a maintenance protocol. The MST (lymphoma-related survival) for the 21 cats was 214 days. The MST was 214 days for cats with mediastinal lymphoma (n = 13), but it was not reached for multicentric lymphoma (n = 8; CONCLUSIONS AND RELEVANCE: The LOPH protocol was well tolerated by cats with lymphoma and persistent FeLV viremia, and resulted in a better MST than similar studies with other protocols. Novel studies and controlled trials are necessary in order to evaluate the efficacy of different protocols according to the lymphoma subtype, anatomic form and FeLV status.

Indexed as

Cat DiseasesLeukemia, FelineLymphomaAnimalsAntineoplastic Combined Chemotherapy ProtocolsCatsLeukemia Virus, FelineProspective StudiesVincristineVincristineCancerdoxorubicinintraperitoneallomustinelymphoid neoplasiaprednisolonevincristine

Identifiers

PMID32684120
PMCPMC10741351
OpenAlexW3044187177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.